Cargando…

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice

Trials on cardiovascular and renal outcomes in patients with type 2 diabetes have consistently demonstrated that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of diabetic kidney disease (DKD) progression. However, their renal protective mechanisms have yet to be completely unders...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zi, Murakoshi, Maki, Ichikawa, Saki, Koshida, Takeo, Adachi, Eri, Suzuki, Chigure, Ueda, Seiji, Gohda, Tomohito, Suzuki, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714078/ https://www.ncbi.nlm.nih.gov/pubmed/33098615 http://dx.doi.org/10.1002/2211-5463.13014

Ejemplares similares

Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice
por: Ichikawa, Saki, et al.
Publicado: (2020)

Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease
por: Gohda, Tomohito, et al.
Publicado: (2019)

Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes
por: Murakoshi, Maki, et al.
Publicado: (2022)

Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function
por: Gohda, Tomohito, et al.
Publicado: (2020)

Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice
por: Murakoshi, Maki, et al.
Publicado: (2021)

Development of an In-House EphA2 ELISA for Human Serum and Measurement of Circulating Levels of EphA2 in Hypertensive Patients with Renal Dysfunction
por: Murakoshi, Maki, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials
por: Gohda, Tomohito, et al.
Publicado: (2022)

Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease
por: Murakoshi, Maki, et al.
Publicado: (2020)

Beneficial effects of tonsillectomy plus steroid pulse therapy on inflammatory and tubular markers in patients with IgA nephropathy
por: Maruyama, Shuntaro, et al.
Publicado: (2016)

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
por: Suzuki, M, et al.
Publicado: (2014)

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
por: Koshida, Takeo, et al.
Publicado: (2023)

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
por: Nunoi, Kiyohide, et al.
Publicado: (2018)

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
por: Hanaguri, Junya, et al.
Publicado: (2022)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
por: Obara, Koki, et al.
Publicado: (2017)

Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes
por: Kakuda, Hirokazu, et al.
Publicado: (2019)

Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes
por: Kamei, Nozomu, et al.
Publicado: (2018)

Role of Mindin in Diabetic Nephropathy
por: Murakoshi, Maki, et al.
Publicado: (2011)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients
por: Gohda, Tomohito, et al.
Publicado: (2022)

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2020)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Potential Targeting of Renal Fibrosis in Diabetic Kidney Disease Using MicroRNAs
por: Sakuma, Hiroko, et al.
Publicado: (2020)

Continuous extracorporeal treatments in a dialysis patient with COVID-19
por: Nihei, Yoshihito, et al.
Publicado: (2020)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus
por: Nomura, Shosaku, et al.
Publicado: (2023)

Effect of Exercise on Kidney Function, Oxidative Stress, and Inflammation in Type 2 Diabetic KK-A(y) Mice
por: Ishikawa, Yuji, et al.
Publicado: (2012)

Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis
por: Gohda, Tomohito, et al.
Publicado: (2017)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2021)

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus
por: Higashikawa, Toshihiro, et al.
Publicado: (2020)

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis
por: Murakami, Kentaro, et al.
Publicado: (2022)

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
por: Katakami, Naoto, et al.
Publicado: (2021)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
por: Iwamoto, Masahiko, et al.
Publicado: (2022)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus
por: Kamei, Shinji, et al.
Publicado: (2018)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2020)

COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine
por: Fukao, Yusuke, et al.
Publicado: (2021)

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real‐world clinical practice: Results of a 36‐month post‐marketing surveillance study (J‐STEP/LT)
por: Utsunomiya, Kazunori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8f28q5adm1h3qngk50doeb4i0g